Toll Free: 1-888-928-9744

Global and China Drugs for Treatment of Age-related Macular Degeneration Research Report to 2020

Published: Jun 22, 2016 | Pages: 116 | Publisher: QYResearch | Industry: Medical Devices | Report Format: Electronic (PDF)

The global Drugs for Treatment of Age-related Macular Degeneration market was valued at USD 64.83 Billion in 2015, and is projected to reach USD 90 Billion by 2021, at a CAGR of 6.78% between 2016 and 2021. Aging population leads to increase the prevalence of AMD, polypharmacy rates rise, the expected drugs enter the market which is studying, and the market quickly absorb those drugs.

This report studies Drugs for Treatment of Age-related Macular Degeneration in Global and China market, focuses on price, sales, market share and revenue of each type in global China. This report also focuses on the sales (consumption), production and market share of Drugs for Treatment of Age-related Macular Degeneration in Europe and China, forecast to 2020, from 2015.

Split by product types, with sales, revenue, market share and price of each type, as well as the types and each type price of key manufacturers, through interviewing nationwide hospital, in 2015 and 2016, covering 
Eylea 
Conbercept Ophthalmic Injection 
Augentropfen Stulln Mono 
Pegaptanib
Lucentis
Verteporfin Powder for Injection
Avastin

Split by manufacturers, this report focuses on the sales, price of each type, average price of Treatment of Age-related Macular Degeneration, revenue and market share, for each manufacturer in 2015 and 2016. Top players, covering 
Bayer 
Regeneron 
Chengdu Kanghong Biotechnologies 
 Pharma Stulln GmbH 
Eyetech
Pfizer
Novartis Pharma
.

Split by regions, this report focuses on the sales (consumption), market share, growth rate by manufacturer of Drugs for Treatment of Age-related Macular Degeneration in Europe and China, from 2011 to 2020 (forecast), covering 
Europe 
China

With 116 pages, 126 charts and eight chapters, to display the market present situation and future, clearly and deeply.


 
 Table of Content
Global and China Drugs for Treatment of Age-related Macular Degeneration Research Report 2015 to 2020 1 Drugs for Treatment of Age-related Macular Degeneration Overview and Each Type 1.1 Product Overview of Drugs for Treatment of Age-related Macular Degeneration 1.1.1 Definition and Product Scope of Drugs for Treatment of Age-related Macular Degeneration 1.1.2 Global Market Size (Value and Volume) of Drugs for Treatment of Age-related Macular Degeneration 2015-2020 1.1.3 China Market Size (Value and Volume) of Drugs for Treatment of Age-related Macular Degeneration 2015-2020 1.2 Product Segments and Price of Each Type 1.2.1 Product Type of Key Manufacturers 1.2.2 Price List of Each Type in 2015 to 2016 1.2.3 Market Share and Growth Rate of Each Type 1.2.4 Eylea Specification and Price in 2015 and 2016 1.2.5 Conbercept Ophthalmic Injection Specification and Price in 2015 and 2016 1.2.6 Visudyne Specification and Price in 2015 and 2016 1.2.7 Augentropfen Stulln Mono Specification and Price in 2015 and 2016 1.2.8 Pegaptanib Specification and Price in 2015 and 2016 1.2.9 Lucentis Specification and Price in 2015 and 2016 1.2.10 Avastin Specification and Price in 2015 and 2016 1.3 Price List (Interviewed) of Each Type for Key Manufacturers in 2015 and 2016 1.3.1 Price List (Interviewed) of Eylea by Key Manufacturers 1.3.2 Price List (Interviewed) of Conbercept Ophthalmic Injection by Key Manufacturers 1.3.3 Price List (Interviewed) of Visudyne by Key Manufacturers 1.3.4 Price List (Interviewed) of Augentropfen Stulln Mono by Key Manufacturers 1.3.5 Price List (Interviewed) of Pegaptanib by Key Manufacturers 1.3.6 Price List (Interviewed) of Lucentis by Key Manufacturers 1.3.7 Price List (Interviewed) of Avastin by Key Manufacturers 2 Competition Analysis by Manufacturers in Global and China 2.1 Global Market Drugs for Treatment of Age-related Macular Degeneration Sales and Share List of Key Manufacturers 2010 to 2015 2.2 Global Market Drugs for Treatment of Age-related Macular Degeneration Revenue and Share List of Key Manufacturers 2010 to 2015 2.3 Global Drugs for Treatment of Age-related Macular Degeneration Average Price List of Key Manufacturers 2010 to 2015 2.4 China Market Drugs for Treatment of Age-related Macular Degeneration Sales and Share List of Key Manufacturers 2010 to 2015 2.5 China Market Drugs for Treatment of Age-related Macular Degeneration Revenue and Share List of Key Manufacturers 2010 to 2015 2.6 China Drugs for Treatment of Age-related Macular Degeneration Average Price List of Key Manufacturers 2010 to 2015 3 Sales and Revenue Segments of Each Type 2015 to 2016 3.1 Global Sales and Revenue Segments of Each Type 2015 to 2016 3.1.1 Global Sales and Market Share of Each Type 2015 to 2016 3.1.2 Global Revenue and Market Share of Each Type 2015 to 2016 3.2 Eylea Sales and Growth Rate 2015 to 2020 3.3 Conbercept Ophthalmic Injection Sales and Growth Rate 2015 to 2020 3.4 Augentropfen Stulln Mono Sales and Growth Rate 2015 to 2020 3.5 Pegaptanib Sales and Growth Rate 2015 to 2020 3.6 Lucentis Sales and Growth Rate 2015 to 2020 3.7 Avastin Sales and Growth Rate 2015 to 2020 3.8 Verteporfin Powder for Injection Sales and Growth Rate 2015 to 2020 4 Market Segments and Forecast of Drugs for Treatment of Age-related Macular Degeneration by Regions 4.1 Sales (Consumption) and Forecast of Drugs for Treatment of Age-related Macular Degeneration by Regions 2015-2020 4.1.1 Sales and Forecast of Drugs for Treatment of Age-related Macular Degeneration by Regions 2015-2020 4.1.2 Sales Growth Rate Forecast of Drugs for Treatment of Age-related Macular Degeneration by Regions 2015 to 2020 4.2 Price and Forecast of Drugs for Treatment of Age-related Macular Degeneration by Regions 2015 to 2020 4.2.1 Price and Forecast of Drugs for Treatment of Age-related Macular Degeneration by Regions 2015 to 2020 4.2.2 Price Growth Rate Forecast of Drugs for Treatment of Age-related Macular Degeneration by Regions 2015 to 2020 4.3 Europe Market Forecast to 2020 4.3.1 Europe Sales and market share of Drugs for Treatment of Age-related Macular Degeneration 2015 to 2020 4.4 China Market Forecast to 2020 4.4.1 China Sales and market share of Drugs for Treatment of Age-related Macular Degeneration 2015 to 2020 5 Raw Materials and Applications 5.1 Key Raw Materials and Price Analysis for Eylea 5.1.1 Key Raw Materials for Eylea 5.1.2 Price Forecast of Key Raw Materials for Eylea 2016 to 2021 5.2 Key Raw Materials and Price Analysis for Conbercept Ophthalmic Injection 5.2.1 Key Raw Materials for Conbercept Ophthalmic Injection 5.2.2 Price Forecast of Key Raw Materials for Conbercept Ophthalmic Injection 2016 to 2021 5.3 Key Raw Materials and Price Analysis for Verteporfin Powder for Injection 5.3.1 Key Raw Materials for Verteporfin Powder for Injection 5.3.2 Price Forecast of Key Raw Materials for Verteporfin Powder for Injection 2016 to 2021 5.4 Key Raw Materials and Price Analysis for Augentropfen Stulln Mono 5.4.1 Key Raw Materials for Augentropfen Stulln Mono 5.4.2 Price Forecast of Key Raw Materials for Augentropfen Stulln Mono 2016 to 2021 5.5 Key Raw Materials and Price Analysis for Pegaptanib 5.5.1 Key Raw Materials for Pegaptanib 5.5.2 Price Forecast of Key Raw Materials for Pegaptanib 2016 to 2021 5.6 Key Raw Materials and Price Analysis for Lucentis 5.6.1 Key Raw Materials for Lucentis 5.6.2 Price Forecast of Key Raw Materials for Lucentis 2016 to 2021 5.7 Key Raw Materials and Price Analysis for Avastin 5.7.1 Key Raw Materials for Avastin 5.7.2 Price Forecast of Key Raw Materials for Avastin2016 to 2021 6 Key Manufacturers Analysis of Drugs for Treatment of Age-related Macular Degeneration 6.1 Regeneron 6.1.1 Company Basic Information 6.1.2 Eylea (Specification and Price) 6.1.2.1 Eylea 2mg/0.05ml, Price, Sales Value and Market Share of Regeneron 6.1.3 Sales Value, Gross Margin 2011-2016 6.1.3.1 Sales Value, Gross Margin and Growth rate of Regeneron Eylea 2mg/0.05ml 6.1.4 Interviewee, Name and Contact 6.2 Bayer 6.2.1 Company Basic Information 6.2.2 Eylea (Specification and Price) 6.2.2.1 Eylea 2mg/0.05ml, Price, Sales Value and Market Share of Bayer 6.2.3 Sales Value, Gross Margin 2011-2016 6.2.3.1 Sales Value, Gross Margin and Growth rate of Bayer Eylea 2mg/0.05ml 6.2.4 Interviewee, Name and Contact 6.3 Chengdu Kanghong Biotechnologies 6.3.1 Company Basic Information 6.3.2 Conbercept Ophthalmic Injection (Specification and Price) 6.3.2.1 Conbercept Ophthalmic Injection 2mg/0.2ml, Price, Sales Value and Market Share of Chengdu Kanghong Biotechnologies 6.3.2.2 Conbercept Ophthalmic Injection 10mg/1ml, Price, Sales Value and Market Share of Chengdu Kanghong Biotechnologies 6.3.3 Sales Value, Gross Margin 2011-2016 6.3.3.1 Sales Value, Gross Margin and Growth rate of Chengdu Kanghong Biotechnologies Conbercept Ophthalmic Injection 2mg/0.2ml 6.3.3.2 Sales Value, Gross Margin and Growth rate of Chengdu Kanghong Biotechnologies Conbercept Ophthalmic Injection 10mg/1ml 6.3.4 Interviewee, Name and Contact 6.4 Pharma Stulln GmbH 6.4.1 Company Basic Information 6.4.2 Augentropfen Stulln Mono (Specification and Price) 6.4.2.1 Augentropfen Stulln Mono 0.4ml:0.006mg:0.040mg, Price, Sales Value and Market Share of Pharma Stulln GmbH 6.4.3 Sales Value, Gross Margin 2011-2016 6.4.3.1 Sales Value, Gross Margin and Growth rate of Pharma Stulln GmbH Levitra Augentropfen Stulln Mono 0.4ml:0.006mg:0.040mg 6.4.4 Interviewee, Name and Contact 6.5 Pfizer 6.5.1 Company Basic Information 6.5.2 Pegaptanib (Specification and Price) 6.5.2.1 Pegaptanib EQ 0.3MG ACID/0.09ML, Price, Sales Value and Market Share of Pfizer 6.5.3 Sales Value, Gross Margin 2011-2016 6.5.3.1 Sales Value, Gross Margin and Growth rate of Pfizer Pegaptanib EQ 0.3MG ACID/0.09ML 6.5.4 Interviewee, Name and Contact 6.6 Eyetech 6.6.1 Company Basic Information 6.6.2 Pegaptanib (Specification and Price) 6.6.2.1 Pegaptanib EQ 0.3MG ACID/0.09ML, Price, Sales Value and Market Share of Eyetech 6.6.3 Sales Value, Gross Margin 2011-2016 6.6.3.1 Sales Value, Gross Margin and Growth rate of Eyetech Pegaptanib EQ 0.3MG ACID/0.09ML 6.6.4 Interviewee, Name and Contact 6.7 Intas 6.7.1 Company Basic Information 6.7.2 Razumab (Specification and Price) 6.7.2.1 Razumab10mg/ml, Price, Sales Value and Market Share of Intas 6.7.3 Sales Value, Gross Margin 2011-2016 6.7.3.1 Sales Value, Gross Margin and Growth rate of Intas Razumab10mg/ml 6.7.4 Interviewee, Name and Contact 6.8 Novartis Pharma 6.8.1 Company Basic Information 6.8.2 Lucentis (Specification and Price) 6.8.2.1 Lucentis10mg/ml, Price, Sales Value and Market Share of Novartis Pharma 6.8.3 Sales Value, Gross Margin 2011-2016 6.8.3.1 Sales Value, Gross Margin and Growth rate of Novartis Pharma Lucentis10mg/ml 6.8.4 Interviewee, Name and Contact 6.9 Roche 6.9.1 Company Basic Information 6.9.2 Lucentis (Specification and Price) 6.9.2.1 Lucentis10mg/ml, Price, Sales Value and Market Share of Roche 6.9.3 Sales Value, Gross Margin 2011-2016 6.9.3.1 Sales Value, Gross Margin and Growth rate of Roche Lucentis10mg/ml 6.9.4 Interviewee, Name and Contact 6.10 LUCKY PHARMA 6.10.1 Company Basic Information 6.10.2 Lucentis (Specification and Price) 6.10.2.1 Lucentis10mg/ml, Price, Sales Value and Market Share of LUCKY PHARMA 6.10.3 Sales Value, Gross Margin 2011-2016 6.10.3.1 Sales Value, Gross Margin and Growth rate of LUCKY PHARMA Lucentis10mg/ml 6.10.4 Interviewee, Name and Contact 6.11 Novartis Pharma 6.11.1 Company Basic Information 6.11.2 Visudyne (Specification and Price) 6.11.2.1 Visudyne 15mg, Price, Sales Value and Market Share of Novartis Pharma 6.11.3 Sales Value, Gross Margin 2011-2016 6.11.3.1 Sales Value, Gross Margin and Growth rate of Novartis Pharma Visudyne15mg 6.11.4 Interviewee, Name and Contact 6.12 Whyte Chemicals 6.12.1 Company Basic Information 6.12.2 Verteporfin Powder for Injection (Specification and Price) 6.12.2.1 Verteporfin Powder for Injection 15mg, Price, Sales Value and Market Share of Whyte Chemicals 6.12.3 Sales Value, Gross Margin 2011-2016 6.12.3.1 Sales Value, Gross Margin and Growth rate of Whyte Chemicals Verteporfin Powder for Injection15mg 6.12.4 Interviewee, Name and Contact 6.13 KEMPROTEC 6.13.1 Company Basic Information 6.13.2 Verteporfin Powder for Injection (Specification and Price) 6.13.2.1 Verteporfin Powder for Injection 15mg, Price, Sales Value and Market Share of KEMPROTEC 6.13.3 Sales Value, Gross Margin 2011-2016 6.13.3.1 Sales Value, Gross Margin and Growth rate of KEMPROTEC Verteporfin Powder for Injection15mg 6.13.4 Interviewee, Name and Contact 6.14 LGM Pharma 6.14.1 Company Basic Information 6.14.2 Verteporfin Powder for Injection (Specification and Price) 6.14.2.1 Verteporfin Powder for Injection 15mg, Price, Sales Value and Market Share of LGM Pharma 6.14.3 Sales Value, Gross Margin 2011-2016 6.14.3.1 Sales Value, Gross Margin and Growth rate of LGM Pharma Verteporfin Powder for Injection15mg 6.14.4 Interviewee, Name and Contact 6.15 MedChemexpress LLC 6.15.1 Company Basic Information 6.15.2 Verteporfin Powder for Injection (Specification and Price) 6.15.2.1 Verteporfin Powder for Injection 15mg, Price, Sales Value and Market Share of MedChemexpress LLC 6.15.3 Sales Value, Gross Margin 2011-2016 6.15.3.1 Sales Value, Gross Margin and Growth rate of MedChemexpress LLC Verteporfin Powder for Injection15mg 6.15.4 Interviewee, Name and Contact 6.16 BOC Sciences 6.16.1 Company Basic Information 6.16.2 Verteporfin Powder for Injection (Specification and Price) 6.16.2.1 Verteporfin Powder for Injection 15mg, Price, Sales Value and Market Share of BOC Sciences 6.16.3 Sales Value, Gross Margin 2011-2016 6.16.3.1 Sales Value, Gross Margin and Growth rate of BOC Sciences Verteporfin Powder for Injection15mg 6.16.4 Interviewee, Name and Contact 6.17 Alfa Chemistry 6.17.1 Company Basic Information 6.17.2 Verteporfin Powder for Injection (Specification and Price) 6.17.2.1 Verteporfin Powder for Injection 15mg, Price, Sales Value and Market Share of Alfa Chemistry 6.17.3 Sales Value, Gross Margin 2011-2016 6.17.3.1 Sales Value, Gross Margin and Growth rate of Alfa Chemistry Verteporfin Powder for Injection15mg 6.17.4 Interviewee, Name and Contact 6.18 Roche 6.18.1 Company Basic Information 6.18.2 Avastin (Specification and Price) 6.16.2.1 Avastin 100mg(4ml)/bottle, Price, Sales Value and Market Share of Roche 6.16.2.2 Avastin 400mg(16ml)/bottle, Price, Sales Value and Market Share of Roche 6.18.3 Sales Value, Gross Margin 2011-2016 6.18.3.1 Sales Value, Gross Margin and Growth rate of Roche Avastin 100mg(4ml)/bottle 6.18.3.2 Sales Value, Gross Margin and Growth rate of Roche Avastin 400mg(16ml)/bottle 6.18.4 Interviewee, Name and Contact 7 Technology Development Trend 7.1 Manufacturing Process of Drugs for Treatment of Erectile Dysfunction 7.2 Analysis of Manufacturing Process 7.3 Development Trend 8 Worldwide, an estimated time for the drug in Erectile Dysfunction research to market 9 Patent expiration time analysis 9.1 Viagra patent expires in China and sales 9.2 Cialis patent expires in China and sales 9.3 Levitra patent expires in China and sales 10 Research Findings and Conclusion
List of Tables and Figures
Figure Picture of Drugs for Treatment of Age-related Macular Degeneration Figure Global Market Size (Value) of Drugs for Treatment of Age-related Macular Degeneration 2015-2020 Figure Global Market Size (Volume) of Drugs for Treatment of Age-related Macular Degeneration 2015-2020 Figure China Market Size (Value) of Drugs for Treatment of Age-related Macular Degeneration2015-2020 Figure China Market Size (Volume) of Drugs for Treatment of Age-related Macular Degeneration 2015-2020 Table Product Type of Key Manufacturers Table Price List of Each Type Table Market Share of Each Type Figure Growth Rate of Each Type 2015 to 2016 Figure Picture of Eylea Table Specification and Price of Eylea in 2015 and 2016 Figure Picture of Conbercept Ophthalmic Injection Table Specification and Price of Conbercept Ophthalmic Injection in 2015 and 2016 Figure Picture of Visudyne Table Specification and Price of Visudyne in 2015 and 2016 Figure Picture of Augentropfen Stulln Mono Table Specification and Price of Augentropfen Stulln Mono in 2015 and 2016 Figure Picture of Pegaptanib Table Specification and Price of Pegaptanib in 2015 and 2016 Figure Picture of Lucentis Table Specification and Price of Lucentis in 2015 and 2016 Figure Picture of Avastin Table Specification and Price of Avastin in 2015 and 2016 Table Price List (Interviewed) of Eylea by Key Manufacturers in 2015 and 2016 Table Price List (Interviewed) of Conbercept Ophthalmic Injection by Key Manufacturers in 2015 and 2016 Table Price List (Interviewed) of Visudyne by Key Manufacturers in 2015 and 2016 Table Price List (Interviewed) of Augentropfen Stulln Mono Tablets by Key Manufacturers in 2015 and 2016 Table Price List (Interviewed) of Pegaptanib Tablets by Key Manufacturers in 2015 and 2016 Table Price List (Interviewed) of Lucentis Tablets by Key Manufacturers in 2015 and 2016 Table Price List (Interviewed) of Avastin Tablets by Key Manufacturers in 2015 and 2016 Table Global Market Drugs for Treatment of Age-related Macular Degeneration Sales List of Key Manufacturers 2010 to 2015 Table Global Market Drugs for Treatment of Age-related Macular Degeneration Sales Share List of Key Manufacturers 2010 to 2015 Table Global Market Drugs for Treatment of Age-related Macular Degeneration Revenue List of Key Manufacturers 2010 to 2015 Table Global Market Drugs for Treatment of Age-related Macular Degeneration Revenue Share List of Key Manufacturers 2010 to 2015 Table Global Drugs for Treatment of Age-related Macular Degeneration Average Price List of Key Manufacturers 2010 to 2015 Table China Market Drugs for Treatment of Age-related Macular Degeneration Sales List of Key Manufacturers 2010 to 2015 Table China Market Drugs for Treatment of Age-related Macular Degeneration Sales Share List of Key Manufacturers 2010 to 2015 Table China Market Drugs for Treatment of Age-related Macular Degeneration Revenue List of Key Manufacturers 2010 to 2015 Table China Market Drugs for Treatment of Age-related Macular Degeneration Revenue Share List of Key Manufacturers 2010 to 2015 Table China Drugs for Treatment of Age-related Macular Degeneration Average Price List of Key Manufacturers 2010 to 2015 Table Global Sales of Each Type 2015 to 2016 Table Global Sales Market Share of Each Type 2015 to 2016 Table Global Revenue of Each Type 2015 to 2016 Table Global Revenue Market Share of Each Type 2015 to 2016 Figure EyleaSales and Growth Rate 2015 to 2020 Figure Conbercept Ophthalmic Injection Sales and Growth Rate 2015 to 2020 Figure Augentropfen Stulln Mono Sales and Growth Rate 2015 to 2020 Figure Pegaptanib Sales and Growth Rate 2015 to 2020 Figure Lucentis Sales and Growth Rate 2015 to 2020 Figure Avastin Sales and Growth Rate 2015 to 2020 Figure Verteporfin Powder for Injection Sales and Growth Rate 2015 to 2020 Table Sales and Forecast of Drugs for Treatment of Age-related Macular Degeneration by Regions 2015-2020 Figure Sales Growth Rate Forecast of Drugs for Treatment of Age-related Macular Degeneration by Regions 2015 to 2020 Table Price and Forecast of Drugs for Treatment of Age-related Macular Degeneration by Regions 2015 to 2020 Figure Price Growth Rate Forecast of Drugs for Treatment of Age-related Macular Degeneration by Regions 2015 to 2020 Table Europe Sales and market share of Drugs for Treatment of Age-related Macular Degeneration 2015 to 2020 Table China Sales and market share of Drugs for Treatment of Age-related Macular Degeneration 2015 to 2020 Table Key Raw Materials for Eylea Table Price Forecast of Key Raw Materials for Eylea Table Key Raw Materials for Conbercept Ophthalmic Injection Table Price Forecast of Key Raw Materials for Conbercept Ophthalmic Injection Table Key Raw Materials for Verteporfin Powder for Injection Table Price Forecast of Key Raw Materials for Verteporfin Powder for Injection Table Key Raw Materials for Augentropfen Stulln Mono Table Price Forecast of Key Raw Materials for Augentropfen Stulln Mono Table Key Raw Materials for Pegaptanib Table Price Forecast of Key Raw Materials for Pegaptanib Table Key Raw Materials for Lucentis Table Price Forecast of Key Raw Materials for Lucentis Table Key Raw Materials for Avastin Table Price Forecast of Key Raw Materials for Avastin Table Regeneron Basic Information List Table Bayer Basic Information List Table Chengdu Kanghong Biotechnologies Basic Information List Table Pharma Stulln GmbH Basic Information List Table Pfizer by Share Ltd Basic Information List Table Eyetech Basic Information List Table Intas Basic Information List Table Novartis Pharma Basic Information List Table Roche Basic Information List Table LUCKY PHARMA Basic Information List Table Novartis Pharma Basic Information List Table Whyte Chemicals Basic Information List Table KEMPROTEC Basic Information List Table LGM Pharma Basic Information List Table MedChemexpress LLC Basic Information List Table BOC Sciences Basic Information List Table Alfa Chemistry Basic Information List Table Roche Basic Information List



To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...

Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3D

Read More...

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...

Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet o

Read More...

Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmace

Read More...
Choose License Type
Single User - US $2250
Multi User - US $2250
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify